Sustained-release composition, method for fabricating, and use thereof

Abstract

A sustained-release composition is provided in the present disclosure for producing a therapeutic gas, such as hydrogen. The sustained-release composition includes a precursor and a carrier. The precursor is magnesium, and the carrier is for carrying the precursor with an efficient amount, wherein the carrier includes a poly lactic-co-glycolic acid copolymer.

What is claimed is: 
     
         1 . A sustained-release composition for producing a therapeutic gas, consisting of:
 a precursor being magnesium; and   a carrier for carrying the precursor with an efficient amount, wherein the carrier comprises a poly lactic-co-glycolic acid copolymer.   
     
     
         2 . The sustained-release composition of  claim 1 , wherein a copolymerization ratio of polylactic acid in the poly lactic-co-glycolic acid copolymer ranges from 50 wt % to 80 wt %, and a copolymerization ratio of polyglycolic acid in the poly lactic-co-glycolic acid copolymer ranges from 20 wt % to 50 wt %. 
     
     
         3 . The sustained-release composition of  claim 1 , wherein the sustained-release composition is a microsphere with an average particle size ranging from 0.2 μm to 300 μm. 
     
     
         4 . The sustained-release composition of  claim 1 , wherein the sustained-release composition contains 1 wt % to 50 wt % of the magnesium based on the total weight of the sustained-release composition. 
     
     
         5 . The sustained-release composition of  claim 1 , wherein a particle size of the magnesium is smaller than or equal to 100 μm. 
     
     
         6 . A method for fabricating the sustained-release composition of  claim 1 , comprising:
 providing a first solution as an oil phase, wherein the first solution comprises the poly lactic-co-glycolic acid copolymer, the precursor and a solvent;   providing a second solution as a water phase;   performing a single emulsification by mixing the first solution and the second solution for forming the sustained-release composition; and   collecting the sustained-release composition.   
     
     
         7 . The method of  claim 6 , wherein a copolymerization ratio of polylactic acid in the poly lactic-co-glycolic acid copolymer ranges from 50 wt % to 80 wt %, and a copolymerization ratio of polyglycolic acid in the poly lactic-co-glycolic acid copolymer ranges from 20 wt % to 50 wt %. 
     
     
         8 . The method of  claim 6 , wherein a mixing ratio of a volume of the first solution to a volume of the second solution ranges from 1:1 to 1:12 in the step of performing the single emulsification. 
     
     
         9 . The method of  claim 6 , wherein the solvent provided in the step of providing the first solution is dichloromethane, trichloromethane or ethyl acetate. 
     
     
         10 . The method of  claim 6 , wherein the second solution is a solution containing polyvinyl alcohol, sodium lauryl sulfate, dimethylaminoborane, or a polyoxyethylene-polyoxypropylene block copolymer. 
     
     
         11 . The method of  claim 6 , wherein a particle size of the magnesium is smaller than or equal to 100 μm. 
     
     
         12 . A method for treating indications for hydrogen therapy, comprising:
 administering an effective amount of the sustained-release composition of  claim 1  to a subject suffered from the indications for hydrogen therapy.   
     
     
         13 . The method of  claim 12 , wherein a copolymerization ratio of polylactic acid in the poly lactic-co-glycolic acid copolymer ranges from 50 wt % to 80 wt %, and a copolymerization ratio of polyglycolic acid in the poly lactic-co-glycolic acid copolymer ranges from 20 wt % to 50 wt %.